
浏览全部资源
扫码关注微信
重庆医科大学附属第一医院神经内科,重庆 400016
龙 波,Email:602011469@qq.com, 研究方向:脑血管病生物标志物的研究。
魏有东,Email:havonewei@163.com。
收稿:2022-12-31,
修回:2023-04-05,
录用:2023-04-13,
纸质出版:2023-06-28
移动端阅览
龙波,田章林,熊密,等.血清固醇调节元件结合蛋白2与急性脑梗死相关性研究[J].重庆医科大学学报,2023,48(6):628-635.
Long Bo,Tian Zhanglin,Xiong Mi,et al.Correlation between serum sterol regulatory element binding protein-2 and acute cerebral infarction[J].Journal of Chongqing Medical University,2023,48(6):628-635.
龙波,田章林,熊密,等.血清固醇调节元件结合蛋白2与急性脑梗死相关性研究[J].重庆医科大学学报,2023,48(6):628-635. DOI: 10.13406/j.cnki.cyxb.003249.
Long Bo,Tian Zhanglin,Xiong Mi,et al.Correlation between serum sterol regulatory element binding protein-2 and acute cerebral infarction[J].Journal of Chongqing Medical University,2023,48(6):628-635. DOI: 10.13406/j.cnki.cyxb.003249.
目的
2
探讨血清固醇调节元件结合蛋白2(sterol regulatory element binding protein-2,SREBP-2)与急性脑梗死的相关性。
方法
2
纳入2020年10月至2021年3月入住的134名急性脑梗死患者和34名健康体检者。通过酶联免疫吸附实验法(enzyme-linked immunosorbent assay,ELISA)检测血清SERBP-2浓度,并依据急性卒中Org 10 172治疗试验(trial of Org 10 172 in acute stroke treatment,TOAST)分型和是否合并糖尿病进行亚组分析。使用美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分评估患者的病情严重程度,并分析血清SREBP-2与病情严重程度的相关性。使用改良Rankin量表评估患者的90 d功能预后,并将患者分为预后良好组和预后不良组,比较2组的血清SREBP-2浓度差异,并通过logistic回归分析血清SREBP-2是否与脑梗死预后相关。
结果
2
脑梗死组的血清SREBP-2浓度明显低于对照组[72.60(57.50,83.35) ng/mL vs. 86.80(77.20,97.90) ng/mL,
P
=0.000]。血清SREBP-2浓度识别急性脑梗死患者和健康人群的曲线下面积为0.782(
P
=0.000)。大动脉粥样硬化型、心源性栓塞型、小动脉闭塞型脑梗死血清SREBP-2浓度均明显低于对照组(
P
=0.000,
P
=0.003,
P
=0.000)。合并糖尿病患者的血清SREBP-2高于不合并糖
尿病的患者(
P
=0.021)。血清SREBP-2浓度与入院NIHSS评分无相关性(
P
>
0.05)。脑梗死患者预后良好组血清SREBP-2浓度较预后不良组低,但差异无统计学意义(
P
>
0.05),logistic回归分析显示血清SREBP-2浓度与脑梗死90 d功能预后无关(
OR
=1.016,95%CI=0.991~1.042,
P
=0.205)。
结论
2
血清SREBP-2浓度在急性脑梗死患者中明显下降。血清SREBP-2对识别脑梗死患者与健康人群具有一定的效能。然而,血清SREBP-2浓度与患者病情严重程度和预后无关。
Objective
2
To explore the correlation between serum sterol regulatory element binding protein-2(SREBP-2) and acute cerebral infarction(ACI).
Methods
2
From October 2020 to March 2021,134 ACI patients were recruited as the ACI group and 34 healthy individuals were recruited as the control group. Serum SERBP-2 concentration was detected by enzyme-linked immunosorbent assay(ELISA) and subgroup analysis was conducted based on trial of Org 10 172 in acute stroke treatment(TOAST) classification and whether patients had diabetes mellitus. National Institutes of Health Stroke Scale(NIHSS) score was used to evaluate the disease severity of patients and the correlation between serum SREBP-2 and the severity was analyzed. The modified Rankin scale was used to assess the 90-day functional prognosis of the ACI group. The ACI patients were classified into favorable outcomes group and unfavorable outcomes group and serum SREBP-2 concentration of two groups were compared. Logistic regression was used to analyze whether serum SREBP-2 was related to ACI prognosis.
Results
2
Serum SREBP-2 concentration of the ACI group was significantly lower than that of the control group[72.60 (57.50, 83.35) ng/mL vs. 86.80(77.20,97.90) ng/mL,
P
=0.000]. The area under the curve for serum SREBP-2 concentration to identify patients with ACI and healthy people was 0.782(
P
=0.000). Serum SREBP-2 concentrations of subtype of large artery atherosclerosis,cardio-embolism and small artery occlu
sion were all lower than that of the control group(
P
=0.000,
P
=0.003,
P
=0.000). Serum SREBP-2 concentration of ACI patients with diabetes mellitus was higher than those without(
P
=0.021). In the ACI group,serum SREBP-2 concentration was not correlated with the NIHSS score at admission(
P
>
0.05). Serum SREBP-2 concentration of the favorable outcomes group was lower than that of the unfavorable outcomes group,but the difference had no statistical significance(
P
>
0.05). Logistic regression analysis showed that serum SREBP-2 concentration was not associated with 90-day functional prognosis of ACI(
OR
=1.016,95%CI=0.991-1.042,
P
=0.205).
Conclusion
2
Serum SREBP-2 concentration decreases significantly in ACI patients. Serum SREBP-2 has a certain efficacy in identifying patients with ACI and healthy people. However,serum SREBP-2 has no correlation with the severity and prognosis of ACI patients.
Mendelson SJ , Prabhakaran S . Diagnosis and management of transient ischemic attack and acute ischemic stroke:a review [J ] . JAMA , 2021 , 325 ( 11 ): 1088 - 1098 .
王露林 , 张硕杰 , 马 萍 , 等 . SREBP2表达及活性调控的研究进展 [J ] . 中国细胞生物学学报 , 2021 , 43 ( 12 ): 2441 - 2448 .
Wang LL , Zhang SJ , Ma P , et al . Research progress on expression and activity regulation of SREBP2 [J ] . Chin J Cell Biol , 2021 , 43 ( 12 ): 2441 - 2448 .
Shimano H , Sato R . SREBP-regulated lipid metabolism:convergent physiology-divergent pathophysiology [J ] . Nat Rev Endocrinol , 2017 , 13 ( 12 ): 710 - 730 .
Cartagena CM , Burns MP , Rebeck GW . 24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury [J ] . Brain Res , 2010 , 1319 : 1 - 12 .
Chen Z , Martin M , Li Z , et al . Endothelial dysfunction:the role of sterol regulatory element-binding protein-induced NOD-like receptor family pyrin domain-containing protein 3 inflammasome in atherosclerosis [J ] . Curr Opin Lipidol , 2014 , 25 ( 5 ): 339 - 349 .
Kusnadi A , Park SH , Yuan RX , et al . The cytokine TNF promotes transcription factor SREBP activity and binding to inflammatory genes to activate macrophages and limit tissue repair [J ] . Immunity , 2019 , 51 ( 2 ): 241 - 257 . e9.
彭 斌 , 刘 鸣 , 崔丽英 . 与时俱进的新指南:《中国急性缺血性脑卒中诊治指南2018》解读 [J ] . 中华神经科杂志 , 2018 , 51 ( 9 ): 657 - 659 .
Peng B , Liu M , Cui LY . New evidence,new guideline:interpretation of the Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018 [J ] . Chin J Neurol , 2018 , 51 ( 9 ): 657 - 659 .
Malek EG , Elbejjani M , Abbas R , et al . TOAST classification and risk factors of ischemic stroke in Lebanon [J ] . Acta Neurol Scand , 2020 , 141 ( 4 ): 294 - 300 .
Eskioglou E , Huchmandzadeh Millotte M , Amiguet M , et al . National institutes of health stroke scale zero strokes [J ] . Stroke , 2018 , 49 ( 12 ): 3057 - 3059 .
Saver JL , Chaisinanunkul N , Campbell BCV , et al . Standardized nomenclature for modified rankin scale global disability outcomes:consensus recommendations from stroke therapy academic industry roundtable XI [J ] . Stroke , 2021 , 52 ( 9 ): 3054 - 3062 .
Yang YJ , Yang Q , Yang J , et al . Angiotensin II induces cholesterol accumulation and injury in podocytes [J ] . Sci Rep , 2017 , 7 ( 1 ): 10672 .
Fowler JWM , Zhang R , Tao B , et al . Inflammatory stress signaling via NF-κB alters accessible cholesterol to upregulate SREBP2 transcriptional activity in endothelial cells [J ] . Elife , 2022 , 11 : e79529 .
Woo CW , Siow YL , Pierce GN , et al . Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors [J ] . Am J Physiol Endocrinol Metab , 2005 , 288 ( 5 ): E1002 - E1010 .
Wang D , Luo YH , Myakala K , et al . Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats [J ] . Sci Rep , 2017 , 7 ( 1 ): 9793 .
Huang Z , Xu AM , Cheung BMY . The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension [J ] . Curr Hypertens Rep , 2017 , 19 ( 4 ): 28 .
Odnoshivkina UG , Kuznetsova EA , Petrov AM . 25-hydroxycholesterol as a signaling molecule of the nervous system [J ] . Biochemistry , 2022 , 87 ( 6 ): 524 - 537 .
Lin FH , Yao XY , Kong C , et al . 25-Hydroxycholesterol protecting from cerebral ischemia-reperfusion injury through the inhibition of STING activity [J ] . Aging , 2021 , 13 ( 16 ): 20149 - 20163 .
Kim JH , Jittiwat J , Ong WY , et al . Changes in cholesterol biosynthetic and transport pathways after excitotoxicity [J ] . J Neurochem , 2010 , 112 ( 1 ): 34 - 41 .
Jeon TI , Osborne TF . SREBPs:metabolic integrators in physiology and metabolism [J ] . Trends Endocrinol Metab , 2012 , 23 ( 2 ): 65 - 72 .
Dang EV , McDonald JG , Russell DW , et al . Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation [J ] . Cell , 2017 , 171 ( 5 ): 1057 - 1071 . e11.
Ma K , Malhotra P , Soni V , et al . Overactivation of intestinal SREBP2 in mice increases serum cholesterol [J ] . PLoS One , 2014 , 9 ( 1 ): e84221 .
Soltanmohammadi E , Piran S , Mohammadi A , et al . Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels;is there a challenge on targeting PCSK9? [J ] . J Med Biochem , 2016 , 35 ( 4 ): 410 - 415 .
Ishikawa M , Iwasaki Y , Yatoh S , et al . Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice:a new model for lipotoxicity [J ] . J Lipid Res , 2008 , 49 ( 12 ): 2524 - 2534 .
Cui XF , Wei W , Qin X , et al . Comparison of routine hematological indicators of liver and kidney function,blood count and lipid profile in healthy people and stroke patients [J ] . PeerJ , 2020 , 8 : e8545 .
Tan CB , Wang ZF , Zheng M , et al . Responses of immune organs after cerebral ischemic stroke [J ] . J Nippon Med Sch , 2021 , 88 ( 3 ): 228 - 237 .
Chen J , Gong JH , Chen HL , et al . Ischemic stroke induces cardiac dysfunction and alters transcriptome profile in mice [J ] . BMC Genomics , 2021 , 22 ( 1 ): 641 .
Arslan BM , Cabalar M , Isiksacan N , et al . Assessment of relationship between serum NT-proBNP levels with clinical features and prognosis in acute ischemic stroke patients [J ] . Neurol India , 2022 , 70 ( 6 ): 2401 - 2406 .
Cao YT , Chen Y , Li XL , et al . Analysis of prognostic risk factors for ischemic stroke in China:a multicentre retrospective clinical study;a national survey in China [J ] . Curr Neurovascular Res , 2022 , 19 ( 1 ): 117 - 126 .
Livingston EH , Cassidy L . Statistical power and estimation of the number of required subjects for a study based on the t -test:a surgeon’s primer [J ] . J Surg Res , 2005 , 126 ( 2 ): 149 - 159 .
0
浏览量
7
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621